RxDoctor Payments Data

Hayley Roberson

Family · Valrico, FLNPI 1710654983

Payments from drug & device makers

$850in general payments, 2019–2025

Across 38 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$132
  • Dynavax Technologies Corporation$122
  • Novo Nordisk$93
  • AstraZeneca$92
  • AbbVie$74
  • Dexcom, Inc.$66
  • plus $271 from 9 others

What the payments were for

  • Food & beverage$850100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$850 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$24,168
Medicare patients
154
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$24,719
EliquisApixaban15$17,662
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,330
MyrbetriqMirabegron14$10,447
FarxigaDapagliflozin Propanediol13$9,983
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$2,659
Atorvastatin Calcium130$1,209
Celecoxib14$918
Omeprazole41$629
Losartan Potassium60$458
Levothyroxine Sodium43$445
Oxybutynin Chloride ErOxybutynin Chloride16$438
Lisinopril55$415
Gabapentin30$386
Fenofibrate17$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$17,66215 claims
AstraZenecaFarxiga$92$9,98313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Valrico

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →